Champions Oncology, Inc. (CSBR) Stock

About Champions Oncology, Inc.

Champions Oncology, Inc. is led by CEO Robert Brainin, employs 210 people, headquartered in US, publicly traded since 2007.

Champions Oncology, Inc. (CSBR) stock trades at $4.72 with a market capitalization of $65.70M. The stock is valued at a negative price-to-earnings (P/E) ratio of -62.53, reflecting a net loss over the last twelve months, price-to-book of 17.64, price-to-sales of 1.13. Over the past 52 weeks the stock has ranged between $4.59 and $8.31, and currently trades 43.2% below its 52-week high.

On profitability, Champions Oncology, Inc. generates a return on equity (ROE) of -27.88% (negative, reflecting a net loss), return on capital employed of -7.16%, an operating margin of 8.77%, a net profit margin of -1.87%.

Champions Oncology, Inc. by the numbers, 2017–2026

Between 2017 and 2026 Champions Oncology, Inc. reported revenue of $15.0M rising to $59.0M, a change of +293.3% across 10 years. Compounded, revenue has grown 7.5% a year over five years, 3.0% over three, 3.5% over the last twelve months. Net profit rose to $-1.0M.

Operating margin went from -44.2% in 2017 to -1.9% in 2026, a gain of 42.3 percentage points. The most recent net margin is -1.87%. On a trailing twelve-month basis to Jun '26, revenue is $61.0M and net profit $-1.0M.

Borrowings stand at $5.0M, cash from operations was $-4.0M in the latest year, positive in 5 of the last 10.

Return on equity has averaged 72.2% over five years, and was -25.0% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Champions Oncology, Inc. (CSBR) — frequently asked questions